NCT04643379View on ClinicalTrials.gov

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 7, 2021

Primary Completion Date

October 16, 2025

Study Completion Date

October 31, 2028

Conditions
Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Olaparib

Supplied by Merck \& Co.

DRUG

Pembrolizumab

Supplied by Merck \& Co.

DRUG

Carboplatin

Commercially available

PROCEDURE

Peripheral blood draw

Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Joseph Sanchez Foundation

UNKNOWN

lead

Washington University School of Medicine

OTHER